My eGFR dropped from 58 to 53 after starting empagliflozin 10 mg. Is my kidney damaged and should I stop?
Public question: "Two weeks after starting empagliflozin 10 mg for type 2 diabetes with CKD stage 3a, my eGFR fell from 58 to 53 mL/min/1.73m². Should I stop?" Evidence Desk answer: A small early dip is expected. SGLT2 inhibitors lower pressure inside the kidney's filters (afferent vasoconstriction), and trial data show an initial average fall of about 3-5 mL/min/1.73m² that then levels off. Over the long term, the drug slows eGFR decline. A drop of 30% or more from baseline, or symptoms of dehydration like dizziness and very low urine output, should prompt a call to your prescriber. Typical practice is to recheck creatinine/eGFR 2-4 weeks after starting, then every 3-6 months, and to check urine albumin-to-creatinine ratio (UACR) at least yearly. Do not stop on your own for a 5-point dip.
The EMPA-KIDNEY trial studied empagliflozin 10 mg daily in adults with eGFR 20-<45, or eGFR 45-<90 with UACR ≥200 mg/g, and showed a lower risk of CKD progression or cardiovascular death. The Jardiance label describes an expected early eGFR dip that is usually reversible, and advises assessing volume status and renal function before starting.